Results from eribulin and capecitabine phase III comparison trial on metastatic breas

[News]

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

More... (http://www.news-medical.net/news/20121210/Results-from-eribulin-and-capecitabine-phase-III-comparison-trial-on-metastatic-breast-cancer.aspx)